Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immunome Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IMNM
Nasdaq
8731
https://immunome.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immunome Inc
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
- Apr 26th, 2024 2:00 pm
Immunome Appoints Sandra M. Swain to Board of Directors
- Apr 25th, 2024 12:26 pm
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
- Apr 5th, 2024 12:00 pm
New Strong Sell Stocks for April 4th
- Apr 4th, 2024 9:56 am
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
- Mar 28th, 2024 8:02 pm
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
- Mar 26th, 2024 12:00 pm
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
- Mar 26th, 2024 12:00 pm
Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions
- Mar 22nd, 2024 10:48 am
Immunome to Participate in the Leerink Partners Global Biopharma Conference
- Mar 7th, 2024 1:00 pm
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
- Mar 1st, 2024 1:00 pm
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
- Feb 20th, 2024 1:15 pm
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
- Feb 20th, 2024 1:00 pm
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Feb 16th, 2024 9:05 pm
Immunome Announces Pricing of Public Offering of Common Stock
- Feb 14th, 2024 3:38 am
Immunome Announces Proposed Public Offering of Common Stock
- Feb 13th, 2024 9:05 pm
Insiders See US$1.25m Investment In Immunome Jump Last Week
- Feb 10th, 2024 12:56 pm
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
- Feb 7th, 2024 1:34 pm
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
- Feb 6th, 2024 1:00 pm
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Feb 5th, 2024 1:00 pm
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
- Jan 8th, 2024 12:00 pm
Scroll